Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trihexyphenidyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 8/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 8/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 5/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 4/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.97 |
| ▸ | HTR1A | P08908 | 2/20 | 0.97 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.97 |
| ▸ | HRH1 | P35367 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | TSHR | P16473 | 2/20 | 0.97 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.97 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.97 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.97 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.97 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cycrimine SCHEMBL1235292 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL30061697 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Procyclidine SCHEMBL121684 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL5502902 | 1.00 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL1320615 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Procyclidine SCHEMBL147344 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL34646 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Cycrimine SCHEMBL249004 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| Trihexyphenidyl SCHEMBL34645 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 | |
| (S)-Procyclidine SCHEMBL519431 | 0.99 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8280 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026089992-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260055183-A1 | ANTI-TREM-1 ANTIBODIES AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2026-02-26 | — | — | US | claimed |
| EP-4306959-B1 | METHOD FOR DETERMINING DETERIORATION OF A DISEASE CONDITION OF A PARKINSON'S DISEASE PATIENT | YAKULT HONSHA KK (JP) | 2026-02-18 | — | — | EP | claimed |
| US-20260000910-A1 | METHOD FOR TREATING PARKINSON'S DISEASE THROUGH PHOTOSTIMULATION, AND DEVICE USED IN SAID METHOD | TSUBOTA LAB INC (JP) | 2026-01-01 | — | — | US | claimed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| WO-2025245003-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-11-27 | — | — | WO | claimed |
| US-20250353912-A1 | COMPOSITIONS AND METHODS COMPRISING ANTIBODIES THAT BIND TO COVALENT PEPTIDE CONJUGATES | UNIV NEW YORK (US) | 2025-11-20 | — | — | US | claimed |
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4121117-B1 | DESIGNER EXTRACELLULAR VESICLES FOR TREATING EXCITOTOXICITY | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-08 | — | — | EP | claimed |
| EP-4619441-A1 | METHODS OF TREATING CANCER USING ANTI-DDR1 ANTIBODIES | Incendia Therapeutics, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-5221536-A | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement | ALZA CORPORATION (US) | 1993-06-22 | — | — | US | claimed |
| US-5192550-A | Dosage form for treating central nervous system disorders | ALZA CORPORATION (US) | 1993-03-09 | — | — | US | claimed |
| EP-0527835-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT. | ALZA CORP (US) | 1993-02-24 | — | — | EP | claimed |
| EP-0523150-A1 | DEVICE AND METHOD FOR ENHANCED ADMINISTRATION OF PHYSOSTIGMINE | PHARMETRIX CORPORATION (US) | 1993-01-20 | — | — | EP | claimed |
| WO-1991016885-A1 | DOSAGE FORM TO DELIVER AN ANTIPARKINSON AGENT | ALZA CORPORATION (US) | 1991-11-14 | — | — | WO | claimed |
| WO-1991015176-A1 | DEVICE AND METHOD FOR ENHANCED ADMINISTRATION OF PHYSOSTIGMINE | PHARMETRIX CORPORATION (US) | 1991-10-17 | — | — | WO | claimed |
| US-5057321-A | Dosage form comprising drug and maltodextrin | ALZA CORPORATION (US) | 1991-10-15 | — | — | US | claimed |
| US-4945097-A | THERAPY FOR ANOXIA, HYPOXIA, OR ISCHEMIA | G. D. SEARLE & CO. (US) | 1990-07-31 | — | — | US | claimed |
| EP-0361894-A2 | Loading and controlled release of amphiphatic molecules to and from liposomes | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1990-04-04 | — | — | EP | claimed |
| US-4788063-A | FATTY ACID, CHOLINERGIC OR ANTICHOLINERGIC AGENT | STATE OF ISRAEL, REPRESENTED BY PRIME MINISTER'S OFFICE ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 1988-11-29 | — | — | US | claimed |